文献速递真实世界研究与卫生经济医学人工智能与信息学

美国公共资助环境下健康信息技术干预对HIV关怀参与及病毒抑制的成本效果分析

Health information technology interventions and engagement in HIV care and achievement of viral suppression in publicly funded settings in the US: A cost-effectiveness analysis.
PubMed 文献 · PLoS Med · 2021-04-07

该研究从卫生系统视角评估了2008至2012年间在Ryan White HIV/AIDS项目示范点实施的6项健康信息技术干预的成本效果。干预包括利用HIV监测数据识别脱管者、扩展电子健康记录访问、电子实验室医嘱与处方、患者门户等。总体干预成本为3,913,313美元,覆盖3,110人。其中4项干预具有成本效果且节约成本(每投入1美元节约6.87至14.91美元),而2项扩展电子健康记录访问的干预无效且不具成本效果。

要点

  • 利用HIV监测数据识别脱管者等4项干预具有成本效果且节约成本。
  • 扩展电子健康记录访问的2项干预无效且不具成本效果。
  • 多数干预在所有敏感性分析场景下保持节约成本或不具成本效果。

核心结论

  • 健康信息技术作为工具可支持HIV快速有效治疗以实现持续病毒抑制。
  • 4项干预不仅具有成本效果且节约成本,每投入1美元节约6.87至14.91美元。
  • 2项扩展电子健康记录访问的干预无效且不具成本效果。

研究设计与样本

  • 成本效果分析,从卫生系统视角评估6项健康信息技术干预。
  • 干预于2008至2012年在美国6个示范点实施。
  • 采用标准微观成本法估算成本(2018年美元),并分析电子患者记录样本。
  • 使用马尔可夫模型估算额外医疗成本和节省的质量调整生命年。

主要发现

  • 总体干预成本为3,913,313美元(范围287,682至998,201美元),覆盖3,110人(范围258至1,181人),历时3年。
  • 处方ART比例变化从站点4下降(87.0%至72.7%)到站点6上升(74.6%至94.2%)。
  • CD4细胞计数0至200个/mm3比例变化从站点6下降(20.2%至11.0%)到站点2上升(16.7%至30.2%)。
  • 不可检测病毒载量比例变化从站点1下降(84.6%至46.0%)到站点5上升(67.0%至69.9%)。

临床怎么用

  • 支持使用健康信息技术增强HIV快速有效治疗以实现持续病毒抑制。
  • 健康信息技术有潜力提高服务利用率、改善健康结果并减少后续HIV传播。

局限性

  • 缺乏同期对照,仅能比较站点自身基线而非同期标准治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The US National HIV/AIDS Strategy (NHAS) emphasizes the use of technology to facilitate coordination of comprehensive care for people with HIV. We examined cost-effectiveness from the health system perspective of 6 health information technology (HIT) interventions implemented during 2008 to 2012 in a Ryan White HIV/AIDS Program (RWHAP) Special Projects of National Significance (SPNS) Program demonstration project. METHODS/FINDINGS: HIT interventions were implemented at 6 sites: Bronx, New York; Durham, North Carolina; Long Beach, California; New Orleans, Louisiana; New York, New York (2 sites); and Paterson, New Jersey. These interventions included: (1) use of HIV surveillance data to identify out-of-care individuals; (2) extension of access to electronic health records (EHRs) to support service providers; (3) use of electronic laboratory ordering and prescribing; and (4) development of a patient portal. We employed standard microcosting techniques to estimate costs (in 2018 US dollars) associated with intervention implementation. Data from a sample of electronic patient records from each demonstration site were analyzed to compare prescription of antiretroviral therapy (ART), CD4 cell counts, and suppression of viral load, before and after implementation of interventions. Markov models were used to estimate additional healthcare costs and quality-adjusted life-years saved as a result of each intervention. Overall, demonstration site interventions cost $3,913,313 (range = $287,682 to $998,201) among 3,110 individuals (range = 258 to 1,181) over 3 years. Changes in the proportion of patients prescribed ART ranged from a decrease from 87.0% to 72.7% at Site 4 to an increase from 74.6% to 94.2% at Site 6; changes in the proportion of patients with 0 to 200 CD4 cells/mm3 ranged from a decrease from 20.2% to 11.0% in Site 6 to an increase from 16.7% to 30.2% in Site 2; and changes in the proportion of patients with undetectable viral load ranged from a decrease from 84.6% to 46.0% in Site 1 to an increase from 67.0% to 69.9% in Site 5. Four of the 6 interventions-including use of HIV surveillance data to identify out-of-care individuals, use of electronic laboratory ordering and prescribing, and development of a patient portal-were not only cost-effective but also cost saving ($6.87 to $14.91 saved per dollar invested). In contrast, the 2 interventions that extended access to EHRs to support service providers were not effective and, therefore, not cost-effective. Most interventions remained either cost-saving or not cost-effective under all sensitivity analysis scenarios. The intervention that used HIV surveillance data to identify out-of-care individuals was no longer cost-saving when the effect of HIV on an individual's health status was reduced and when the natural progression of HIV was increased. The results of this study are limited in that we did not have contemporaneous controls for each intervention; thus, we are only able to assess sites against themselves at baseline and not against standard of care during the same time period. CONCLUSIONS: These results provide additional support for the use of HIT as a tool to enhance rapid and effective treatment of HIV to achieve sustained viral suppression. HIT has the potential to increase utilization of services, improve health outcomes, and reduce subsequent transmission of HIV.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Shade SB, Marseille E, Kirby V, et al. Health information technology interventions and engagement in HIV care and achievement of viral suppression in publicly funded settings in the US: A cost-effectiveness analysis. PLoS Med. 2021. PMID: 33826617. doi:10.1371/journal.pmed.1003389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。